Nitasha Sarswat to Double-Blind Method
This is a "connection" page, showing publications Nitasha Sarswat has written about Double-Blind Method.
Connection Strength
0.214
-
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B. J Am Coll Cardiol. 2026 Sep 22; 88(12):1402-1412.
Score: 0.045
-
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial. J Am Heart Assoc. 2026 Oct 06; 15(19):e050566.
Score: 0.045
-
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
Score: 0.044
-
Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Circulation. 2026 Jan 27; 153(4):214-225.
Score: 0.043
-
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 10 26; 389(17):1553-1565.
Score: 0.037